Key Takeaways
- Shares of HIMS experienced a significant rally of approximately 13% on April 16, 2026, driven by FDA announcements regarding peptide regulatory oversight
- FDA confirmed scheduled advisory meetings on July 23-24 to assess multiple peptides for potential addition to the 503A Bulks List
- Bank of America Securities increased its price objective to $25 from a previous $21, while retaining its Neutral outlook
- Analysts characterize this development as a modest long-term catalyst with limited immediate effect on earnings projections
- Company insiders have offloaded roughly $3.4 million in shares over the previous three months, with no corresponding buying activity
Shares of Hims & Hers Health (HIMS) experienced a substantial rally, climbing as high as 13.72% during trading on April 16, 2026. The surge came after the Food and Drug Administration revealed plans to convene advisory committee sessions to review multiple wellness peptides that remain under regulatory restrictions.
Hims & Hers Health, Inc., HIMS
The regulatory agency released a formal notice outlining Pharmacy Compounding Advisory Committee sessions scheduled for July 23 and 24. These gatherings will center on evaluating various peptide-based bulk drug substances for potential addition to the 503A Bulks List. It’s important to note this represents a preliminary procedural action rather than formal authorization.
Public statements from RFK Jr. regarding prospective FDA policy modifications amplified investor optimism. The agency is considering removing restrictions on as many as 12 peptides, with review processes extending through February 2027.
The equity had been gaining momentum prior to this announcement. During the preceding week, HIMS climbed approximately 25%, based on InvestingPro analytics.
Bank of America Upgrades Price Objective
Bank of America Securities reacted to the news by elevating its price target for HIMS to $25 from the prior $21 level, though maintained its Neutral recommendation. The investment bank increased its target valuation multiple to roughly 25.5 times from 21.5 times, pointing to elevated peer multiples and peptide-related opportunities.
The firm highlighted that this regulatory shift could enable the organization to redirect existing GLP-1 compounding infrastructure toward alternative peptides. This consideration is significant because HIMS has capital committed to GLP-1 facilities following previous FDA compounding limitations.
Bank of America exercised caution in its assessment. Analysts characterized the development as “an initial small step” and indicated no anticipated near-term earnings impact absent concrete FDA regulatory action.
The regulatory body also emphasized that a majority of the substances currently under consideration continue to present potential safety concerns according to existing guidance.
Additional HIMS Developments
The telehealth company recently integrated Novo Nordisk’s FDA-sanctioned GLP-1 therapeutics into its service platform, featuring Wegovy in both injectable and oral formulations. The Wegovy tablet represents the sole FDA-cleared GLP-1 weight management pill on the market.
Additionally, the platform will provide Ozempic injection pens, though these carry approval exclusively for Type 2 diabetes management.
Rivalry in the GLP-1 sector has intensified considerably. Amazon Pharmacy recently launched same-day delivery for Eli Lilly’s freshly approved GLP-1 medication Foundayo, creating competitive challenges for both Novo Nordisk and HIMS.
Regarding insider transactions, CFO Oluyemi Okupe submitted filings to divest shares worth approximately $4.9 million. During the past three-month period, company insiders have collectively sold about $3.4 million in holdings, with zero buying activity documented.
HIMS currently trades at a price-to-earnings multiple in the 45-47x range. InvestingPro’s assessment indicates the stock appears overvalued compared to its Fair Value calculation. The organization maintains a market capitalization of approximately $5.54 billion and serves over 2 million subscribers.
Bank of America’s EBITDA projection for 2026 remains roughly 21% beneath the Wall Street consensus figure, a discrepancy the firm has highlighted in previous research reports.
